Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-707 monotherapy in first-line PD-L1 positive advanced NSCLC
NCT06361927Phase 2Recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tivunatamig in non-small cell lung cancer (NSCLC) (6 cohorts), sponsored by 3S Guojian Pharmaceutical. Primary endpoint: Overall Response Rate at 12 months. Started May 2024; status: recruiting.
02
Drugs
tivunatamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06361927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361927.